SENTIS™ Cancer+ Discovery Testing provides patients with one of the market’s most comprehensive and accurate NGS-based testing solution for the identification of actionable somatic and germline mutations and the discovery of novel variants with important functions in cancer.

The panel offers 816 cancer-related genes and interrogates the most common types of alterations, including SNVs, indels, CNVs and fusions in solid tumors, which provides comprehensive medication guidance on targeted therapy, chemotherapy, and immunotherapy for patients with solid tumors, as well as hereditary tumor risk assessment, to comprehensively assist patients in finding treatment options that may be of benefit.

Applicable Clinical Scenarios

• Patients with solid tumor in early and mid-stage before neoadjuvant therapy
• Patients with solid tumor in early and mid-stage before adjuvant therapy
• Patients with solid tumor in advanced stage before first-line treatment
• Patients with solid tumor in advanced who need to find the cause of drug resistance and adjust their treatment plan after drug resistance